Mercer Global Advisors
CTKB icon

Mercer Global Advisors’s Cytek Biosciences CTKB Stock Holding History

Mercer Global Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Sell
25,718
-3,397
-12% -$14.5K ﹤0.01% 3396
2026
Q1 		$127K Buy
29,115
+7,389
+34% +$34.9K ﹤0.01% 2963
2025
Q4 		$110K Sell
21,726
-8
-0% -$37 ﹤0.01% 2696
2025
Q3 		$75.4K Buy
+21,734
New +$81.6K ﹤0.01% 2560

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mercer Global Advisors's CTKB Position: Q2 2026 in Review

Mercer Global Advisors reduced its Cytek Biosciences (CTKB) stake by 12% in Q2 2026, selling an estimated $14.5K and leaving 25,718 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #3396.

Mercer Global Advisors first reported a position in CTKB in Q3 2025 and has held it in 4 quarters since. The position peaked at $127K in Q1 2026. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Mercer Global Advisors held 25,718 shares of Cytek Biosciences worth $114K as of Q2 2026.
  • Mercer Global Advisors sold 3,397 Cytek Biosciences shares in Q2 2026, an estimated $14.5K.
  • Cytek Biosciences made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3396 holding.
  • Mercer Global Advisors first reported a position in Cytek Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Mercer Global Advisors's Cytek Biosciences position peaked at $127K in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.